抑瘤素M在肺部疾病及惡病質中的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

柯章敏 ^1,2 , 潘航程 ² , 王麗 ² , 呂鏜烽 ¹ ,  張秀偉 ² ,  宋勇 ¹

1. ;
2. ;

Corresponding?author：

張秀偉, Email: zhangxiuweiywy@126.com; 宋勇, Email: yong_song6310@yahoo.com

Keywords：

DOI：

10.7507/1671-6205.202401039

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 柯章敏, 潘航程, 王麗, 呂鏜烽, 張秀偉, 宋勇. 抑瘤素M在肺部疾病及惡病質中的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2024, 23(12): 900-904. doi: 10.7507/1671-6205.202401039 Copy

1.	Wolf CL, Pruett C, Lighter D, et al. The clinical relevance of OSM in inflammatory diseases: a comprehensive review. Front Immunol, 2023, 14: 1239732.
2.	Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol, 2018, 18(12): 773-789.
3.	Liu T, Wang Q, Zhou L, et al. Intrahepatic paracrine signaling by cardiotrophin-like cytokine factor 1 ameliorates diet-induced NASH in mice. Hepatology, 2023, 78(5): 1478-1491.
4.	Zarling JM, Shoyab M, Marquardt H, et al. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci, 1986, 83(24): 9739-9743.
5.	Deller MC, Hudson KR, Ikemizu S, et al. Crystal structure and functional dissection of the cytostatic cytokine oncostatin M. Structure, 2000, 8(8): 863-874.
6.	Chen M, Ren R, Lin W, et al. Exploring the oncostatin M (OSM) feed-forward signaling of glioblastoma via STAT3 in pan-cancer analysis. Cancer Cell Int, 2021, 21(1): 565.
7.	Kucia-Tran JA, Tulkki V, Scarpini CG, et al. Anti-oncostatin M antibody inhibits the pre-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma. J Pathol, 2018, 244(3): 283-295.
8.	Polak KL, Tamagno I, Parameswaran N, et al. Oncostatin-M and OSM-Receptor Feed-Forward Activation of MAPK Induces Separable Stem-like and Mesenchymal Programs. Mol Cancer Res, 2023, 21(9): 975-990.
9.	O'Brien A, Hanlon MM, Marzaioli V, et al. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function. Front Immunol, 2021, 12: 672461.
10.	Han NR, Ko SG, Park HJ, Moon PD. Dexamethasone Attenuates Oncostatin M Production via Suppressing of PI3K/Akt/NF-κB Signaling in Neutrophil-like Differentiated HL-60 Cells. Molecules, 2021, 27(1): 129.
11.	Pereira de Sousa FL, Chaiwangyen W, Morales-Prieto DM, et al. Involvement of STAT1 in proliferation and invasiveness of trophoblastic cells. Reprod Biol, 2017, 17(3): 218-224.
12.	Liu H, Qiu B, Yang H, et al. AHNAK, regulated by the OSM/OSMR signaling, involved in the development of primary localized cutaneous amyloidosis. J Dermatol Sci, 2023, 110(2): 53-60.
13.	Richards CD, Botelho F. Oncostatin M in the Regulation of Connective Tissue Cells and Macrophages in Pulmonary Disease. Biomedicines, 2019, 7(4): 95.
14.	Mozaffarian A, Brewer AW, Trueblood ES, et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol, 2008, 181(10): 7243-7253.
15.	Esnault S, Bernau K, Torr EE, et al. RNA-sequencing analysis of lung primary fibroblast response to eosinophil-degranulation products predicts downstream effects on inflammation, tissue remodeling and lipid metabolism. Respir Res. 2017, 18(1): 188.
16.	O'Donoghue RJ, Knight DA, Richards CD, et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med. 2012, 4(9): 939-951.
17.	Wong S, Botelho FM, Rodrigues RM, Richards CD. Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 Dysregulation in lungs of fibrosis-resistant BALB/c mice. Lab Invest, 2014, 94(9): 1003-1016.
18.	Myll?rniemi M, Lindholm P, Ryyn?nen MJ, et al. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med, 2008, 177(3): 321-329.
19.	Ayaub EA, Dubey A, Imani J, et al. Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis. Sci Rep, 2017, 7(1): 13281.
20.	Nagahama KY, Togo S, Holz O, et al. Oncostatin M modulates fibroblast function via signal transducers and activators of transcription proteins-3. Am J Respir Cell Mol Biol, 2013, 49(4): 582-591.
21.	Lan YW, Theng SM, Huang TT, et al. Oncostatin M-Preconditioned Mesenchymal Stem Cells Alleviate Bleomycin-Induced Pulmonary Fibrosis Through Paracrine Effects of the Hepatocyte Growth Factor. Stem Cells Transl Med, 2017, 6(3): 1006-1017.
22.	Simpson JL, Baines KJ, Boyle MJ, Scott RJ, Gibson PG. Oncostatin M (OSM) is increased in asthma with incompletely reversible airflow obstruction. Exp Lung Res, 2009, 35(9): 781-794.
23.	Headland SE, Dengler HS, Xu D, et al. Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma. Sci Transl Med, 2022, 14(627): eabf8188.
24.	Baines KJ, Simpson JL, Gibson PG. Innate immune responses are increased in chronic obstructive pulmonary disease. PLoS One. 2011;6(3): e18426.
25.	Lin K, Wang T, Tang Q, et al. IL18R1-Related Molecules as Biomarkers for Asthma Severity and Prognostic Markers for Idiopathic Pulmonary Fibrosis. J Proteome Res, 2023, 22(10): 3320-3331.
26.	Ho L, Yip A, Lao F, Botelho F, Richards CD. RELMα is Induced in Airway Epithelial Cells by Oncostatin M Without Requirement of STAT6 or IL-6 in Mouse Lungs In Vivo. Cells. 2020;9(6): 1338.
27.	喬艷艷, 傅恩清. 腫瘤相關巨噬細胞在肺癌中的研究進展. 中國肺癌雜志, 2022, 25(1): 34-39.
28.	Ouyang L, Shen LY, Li T, Liu J. Inhibition effect of Oncostatin M on metastatic human lung cancer cells 95-D in vitro and on murine melanoma cells B16BL6 in vivo. Biomed Res, 2006, 27(4): 197-202.
29.	Spence MJ, Streiff R, Day D, Ma Y. Oncostatin M induces tissue-type plasminogen activator and plasminogen activator inhibitor-1 in Calu-1 lung carcinoma cells. Cytokine, 2002, 18(1): 26-34.
30.	McCormick C, Freshney RI. Activity of growth factors in the IL-6 group in the differentiation of human lung adenocarcinoma. Br J Cancer, 2000, 82(4): 881-890.
31.	Cichy J, Pure E. Oncostatin M and transforming growth factor-beta 1 induce post-translational modification and hyaluronan binding to CD44 in lung-derived epithelial tumor cells. J Biol Chem, 2000, 275(24): 18061-18069.
32.	Lauber S, Wong S, Cutz JC, et al. Novel function of Oncostatin M as a potent tumour-promoting agent in lung. Int J Cancer, 2015, 136(4): 831-843.
33.	Shien K, Papadimitrakopoulou VA, Ruder D, et al. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer. Mol Cancer Ther, 2017, 16(10): 2234-2245.
34.	Wysoczynski M, Ratajczak MZ. Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int J Cancer, 2009, 125(7): 1595-1603.
35.	Pan CM, Wang ML, Chiou SH, et al. Oncostatin M suppresses metastasis of lung adenocarcinoma by inhibiting SLUG expression through coordination of STATs and PIASs signalings. Oncotarget, 2016, 7(37): 60395-60406.
36.	Queiroz AL, Dantas E, Ramsamooj S, et al. Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer. Nat Commun, 2022, 13(1): 4633.
37.	Lim S, Deaver JW, Rosa-Caldwell ME, et al. Development of metabolic and contractile alterations in development of cancer cachexia in female tumor-bearing mice. J Appl Physiol (1985), 2022, 132(1): 58-72.
38.	Kir S, White JP, Kleiner S, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature, 2014, 513(7516): 100-104.
39.	Baazim H, Antonio-Herrera L, Bergthaler A. The interplay of immunology and cachexia in infection and cancer. Nat Rev Immunol, 2022, 22(5): 309-321.
40.	Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov, 2015, 14(1): 58-74.
41.	Domaniku-Waraich A, Agca S, Toledo B, et al. Oncostatin M signaling drives cancer-associated skeletal muscle wasting. Cell Rep Med, 2024, 5(4): 101498.
42.	Miki Y, Morioka T, Shioi A, et al. Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation. Biochem Biophys Res Commun, 2019, 516(3): 951-956.
43.	Bilgic SN, Domaniku A, Toledo B, et al. EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia. Nature, 2023, 617(7962): 827-834.
44.	Choy EH, Bendit M, McAleer D, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials. Arthritis Res Ther, 2013, 15(5): R132.

1. Wolf CL, Pruett C, Lighter D, et al. The clinical relevance of OSM in inflammatory diseases: a comprehensive review. Front Immunol, 2023, 14: 1239732.
2. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol, 2018, 18(12): 773-789.
3. Liu T, Wang Q, Zhou L, et al. Intrahepatic paracrine signaling by cardiotrophin-like cytokine factor 1 ameliorates diet-induced NASH in mice. Hepatology, 2023, 78(5): 1478-1491.
4. Zarling JM, Shoyab M, Marquardt H, et al. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci, 1986, 83(24): 9739-9743.
5. Deller MC, Hudson KR, Ikemizu S, et al. Crystal structure and functional dissection of the cytostatic cytokine oncostatin M. Structure, 2000, 8(8): 863-874.
6. Chen M, Ren R, Lin W, et al. Exploring the oncostatin M (OSM) feed-forward signaling of glioblastoma via STAT3 in pan-cancer analysis. Cancer Cell Int, 2021, 21(1): 565.
7. Kucia-Tran JA, Tulkki V, Scarpini CG, et al. Anti-oncostatin M antibody inhibits the pre-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma. J Pathol, 2018, 244(3): 283-295.
8. Polak KL, Tamagno I, Parameswaran N, et al. Oncostatin-M and OSM-Receptor Feed-Forward Activation of MAPK Induces Separable Stem-like and Mesenchymal Programs. Mol Cancer Res, 2023, 21(9): 975-990.
9. O'Brien A, Hanlon MM, Marzaioli V, et al. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function. Front Immunol, 2021, 12: 672461.
10. Han NR, Ko SG, Park HJ, Moon PD. Dexamethasone Attenuates Oncostatin M Production via Suppressing of PI3K/Akt/NF-κB Signaling in Neutrophil-like Differentiated HL-60 Cells. Molecules, 2021, 27(1): 129.
11. Pereira de Sousa FL, Chaiwangyen W, Morales-Prieto DM, et al. Involvement of STAT1 in proliferation and invasiveness of trophoblastic cells. Reprod Biol, 2017, 17(3): 218-224.
12. Liu H, Qiu B, Yang H, et al. AHNAK, regulated by the OSM/OSMR signaling, involved in the development of primary localized cutaneous amyloidosis. J Dermatol Sci, 2023, 110(2): 53-60.
13. Richards CD, Botelho F. Oncostatin M in the Regulation of Connective Tissue Cells and Macrophages in Pulmonary Disease. Biomedicines, 2019, 7(4): 95.
14. Mozaffarian A, Brewer AW, Trueblood ES, et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol, 2008, 181(10): 7243-7253.
15. Esnault S, Bernau K, Torr EE, et al. RNA-sequencing analysis of lung primary fibroblast response to eosinophil-degranulation products predicts downstream effects on inflammation, tissue remodeling and lipid metabolism. Respir Res. 2017, 18(1): 188.
16. O'Donoghue RJ, Knight DA, Richards CD, et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med. 2012, 4(9): 939-951.
17. Wong S, Botelho FM, Rodrigues RM, Richards CD. Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 Dysregulation in lungs of fibrosis-resistant BALB/c mice. Lab Invest, 2014, 94(9): 1003-1016.
18. Myll?rniemi M, Lindholm P, Ryyn?nen MJ, et al. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med, 2008, 177(3): 321-329.
19. Ayaub EA, Dubey A, Imani J, et al. Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis. Sci Rep, 2017, 7(1): 13281.
20. Nagahama KY, Togo S, Holz O, et al. Oncostatin M modulates fibroblast function via signal transducers and activators of transcription proteins-3. Am J Respir Cell Mol Biol, 2013, 49(4): 582-591.
21. Lan YW, Theng SM, Huang TT, et al. Oncostatin M-Preconditioned Mesenchymal Stem Cells Alleviate Bleomycin-Induced Pulmonary Fibrosis Through Paracrine Effects of the Hepatocyte Growth Factor. Stem Cells Transl Med, 2017, 6(3): 1006-1017.
22. Simpson JL, Baines KJ, Boyle MJ, Scott RJ, Gibson PG. Oncostatin M (OSM) is increased in asthma with incompletely reversible airflow obstruction. Exp Lung Res, 2009, 35(9): 781-794.
23. Headland SE, Dengler HS, Xu D, et al. Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma. Sci Transl Med, 2022, 14(627): eabf8188.
24. Baines KJ, Simpson JL, Gibson PG. Innate immune responses are increased in chronic obstructive pulmonary disease. PLoS One. 2011;6(3): e18426.
25. Lin K, Wang T, Tang Q, et al. IL18R1-Related Molecules as Biomarkers for Asthma Severity and Prognostic Markers for Idiopathic Pulmonary Fibrosis. J Proteome Res, 2023, 22(10): 3320-3331.
26. Ho L, Yip A, Lao F, Botelho F, Richards CD. RELMα is Induced in Airway Epithelial Cells by Oncostatin M Without Requirement of STAT6 or IL-6 in Mouse Lungs In Vivo. Cells. 2020;9(6): 1338.
27. 喬艷艷, 傅恩清. 腫瘤相關巨噬細胞在肺癌中的研究進展. 中國肺癌雜志, 2022, 25(1): 34-39.
28. Ouyang L, Shen LY, Li T, Liu J. Inhibition effect of Oncostatin M on metastatic human lung cancer cells 95-D in vitro and on murine melanoma cells B16BL6 in vivo. Biomed Res, 2006, 27(4): 197-202.
29. Spence MJ, Streiff R, Day D, Ma Y. Oncostatin M induces tissue-type plasminogen activator and plasminogen activator inhibitor-1 in Calu-1 lung carcinoma cells. Cytokine, 2002, 18(1): 26-34.
30. McCormick C, Freshney RI. Activity of growth factors in the IL-6 group in the differentiation of human lung adenocarcinoma. Br J Cancer, 2000, 82(4): 881-890.
31. Cichy J, Pure E. Oncostatin M and transforming growth factor-beta 1 induce post-translational modification and hyaluronan binding to CD44 in lung-derived epithelial tumor cells. J Biol Chem, 2000, 275(24): 18061-18069.
32. Lauber S, Wong S, Cutz JC, et al. Novel function of Oncostatin M as a potent tumour-promoting agent in lung. Int J Cancer, 2015, 136(4): 831-843.
33. Shien K, Papadimitrakopoulou VA, Ruder D, et al. JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer. Mol Cancer Ther, 2017, 16(10): 2234-2245.
34. Wysoczynski M, Ratajczak MZ. Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int J Cancer, 2009, 125(7): 1595-1603.
35. Pan CM, Wang ML, Chiou SH, et al. Oncostatin M suppresses metastasis of lung adenocarcinoma by inhibiting SLUG expression through coordination of STATs and PIASs signalings. Oncotarget, 2016, 7(37): 60395-60406.
36. Queiroz AL, Dantas E, Ramsamooj S, et al. Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer. Nat Commun, 2022, 13(1): 4633.
37. Lim S, Deaver JW, Rosa-Caldwell ME, et al. Development of metabolic and contractile alterations in development of cancer cachexia in female tumor-bearing mice. J Appl Physiol (1985), 2022, 132(1): 58-72.
38. Kir S, White JP, Kleiner S, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature, 2014, 513(7516): 100-104.
39. Baazim H, Antonio-Herrera L, Bergthaler A. The interplay of immunology and cachexia in infection and cancer. Nat Rev Immunol, 2022, 22(5): 309-321.
40. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov, 2015, 14(1): 58-74.
41. Domaniku-Waraich A, Agca S, Toledo B, et al. Oncostatin M signaling drives cancer-associated skeletal muscle wasting. Cell Rep Med, 2024, 5(4): 101498.
42. Miki Y, Morioka T, Shioi A, et al. Oncostatin M induces C2C12 myotube atrophy by modulating muscle differentiation and degradation. Biochem Biophys Res Commun, 2019, 516(3): 951-956.
43. Bilgic SN, Domaniku A, Toledo B, et al. EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia. Nature, 2023, 617(7962): 827-834.
44. Choy EH, Bendit M, McAleer D, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials. Arthritis Res Ther, 2013, 15(5): R132.

Previous Article
家庭經鼻高流量氧療在慢性阻塞性肺疾病中的應用研究進展
Next Article
動態胸片在呼吸系統疾病診療中的應用進展

Chinese Journal of Respiratory and Critical Care Medicine

抑瘤素M在肺部疾病及惡病質中的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content